---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-016319"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-06-01T23:59:59+00:00"
generated_at: "2026-06-14T09:17:37.806103+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Atossa appoints Greg Weaver as CFO, succeeding Kyle Guse effective June 1, 2023

## Summary
- Greg Weaver appointed EVP and CFO effective June 1, 2023, succeeding Kyle Guse who ceased as of May 26, 2023.
- Weaver receives $450K base salary, 45% target bonus, $125K sign-on, and 2.6M stock options vesting over 4 years.
- Weaver previously served as CFO of BioIntelliSense, Atai Life Sciences, and Eloxx Pharmaceuticals; also a director since 2013.
- Guse will receive severance benefits per his employment agreement upon termination without cause.
- Weaver's severance includes 6 months salary/benefits, or 12 months with equity acceleration upon change of control.

## SEC filing metadata
- accession: 0001437749-23-016319
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-06-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/0001437749-23-016319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/atos20230526_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-016319
- JSON: https://secwatch.observer/filing/0001437749-23-016319.json
- Plain text: https://secwatch.observer/filing/0001437749-23-016319.txt

## Key facts
- Executive change
  Kyle Guse departed as General Counsel and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..
  - Action: ceased to serve
  - Role: General Counsel and Chief Financial Officer
  source text: Mr. Weaver succeeds Kyle Guse, who ceased to serve as the Company’s General Counsel and Chief Financial Officer as of May 26, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/0001437749-23-016319-index.htm
- Executive change
  Greg Weaver was appointed as Executive Vice President and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Executive Vice President and Chief Financial Officer
  source text: Effective as of June 1, 2023 (the “Effective Date”), Atossa Therapeutics, Inc. (the “Company”) appointed Greg Weaver as the Company’s Executive Vice President and Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/0001437749-23-016319-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.